Alluvi, known as BI 4744, presents a promising development in obesity treatment. This dual activator targeting both GLP-1 and GIP targets demonstrates remarkable effectiveness in clinical trials, possibly exceeding https://45listing.com/story24386372/alluvi-a-in-depth-dive-into-the-medication-s-prospects